| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | integrin alpha 2 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify)
| |
Vatelizumab is an immunomodulator. It binds to integrin alpha 2.
It was withdrawn from Phase II trials for inflammatory bowel disease due to a lack of efficacy.